follow up continued until surgery (table) . The haemorrhage stopped in 19 of the 20 patients treated with somatostatin, 13 of the 20 treated with ranitidine, and nine of the 20 treated with placebo. In the patients treated with somatostatin haemorrhage stopped eight to 12 hours after the beginning of treatment; in those treated with ranitidine 20 to 60 hours after; and in the patients treated with placebo 36 to 53 hours after. Statistical analysis of the bleeding time with the log rank test showed a highly significant difference between somatostatin and the other treatments (x2= 48-13, df= 1, p < 0 0001). No significant difference was found between ranitidine and placebo (x2= 1-32, df= 1, p 025). Moreover, no patient treated with somatostatin rebled, while rebleeding occurred in three of the 13 patients treated with ranitidine whose haemorrhage had stopped (18, 24, and 33 Patients were randomly allocated to three groups of 20. The first group underwent somatostatin treatment (an intravenous bolus injection of 250 jig for not less than five minutes followed by continuous infusion of 250 jsg/h with a peristaltic pump). The second group received ranitidine 50 mg intravenously every four hours. In the third group (placebo) treatment comprised only inser tion ofa gastric tube. Haemoglobin concentration and packed cell volume were measured every six hours, and serum glucose, urea, creatinine, and electrolyte concentrations every 12 hours. Each drug used in the study was continued for 12 hours after the first report of clear gastric juice. The haemorrhage was considered to have stopped when in the following 12 hours without any treatment the lavage juice remained clear. Endoscopy was then repeated. In patients in whom the haemorrhage had stopped the endoscopy showed that those with acute haemorrhagic gastropathies had hyperaemic mucosa with no erosions, while those with a gastric or duodenal ulcer had an ulcerative lesion covered by a blood clot that was noticeably adherent and not bleeding.
All patients whose haemorrhage had definitely stopped were examined for 120 hours after the interruption of treatment. In all patients in whom surgery was necessary because the haemorrhage did not stop or because of rebleeding, of treatment) and in two of the nine patients treated with placebo whose haemorrhage had stopped (12 and 22 hours after the interruption of the treatment).
Comment
This comparative study shows that somatostatin is more effective than ranitidine and placebo in the control of iatrogenic gastroduodenal haemorrhages due to acute haemorrhagic gastropathies and to gastric and duodenal ulcer. The cessation of bleeding induced by somatostatin is probably due to the hormone's capacity to reduce secretion of gastric acid and pepsin, serum gastrin concentrations, and splanchnic blood flow, and to its considerable gastric cytoprotective effect. 
